Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intervacc ABFRA:2E9 -4.06%63 PB Ratio is 1.30 as of Jul. 20, 2026, which is 27% below its 10-year median of 1.79. GuruFocus rates FRA:2E9 with a GF Score™ of 63/100 and a GF Value™ of €0.09. The stock has 2 warning signs investors should review. Among 1,231 Biotechnology companies, Intervacc AB ranks better than 70.19% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-20), Intervacc AB's share price is €0.0897. Intervacc AB's Book Value per Share for the quarter that ended in Mar. 2026 was €0.07. Hence, Intervacc AB's PB Ratio of today is 1.30.
The historical rank and industry rank for Intervacc AB's PB Ratio or its related term are showing as below:
FRA:2E9'
s PB Ratio Range Over the Past 10 Years
Min: 0.3 Med: 1.79 Max: 13.5
Current: 1.57
During the past 12 years, Intervacc AB's highest PB Ratio was 13.50. The lowest was 0.30. And the median was 1.79.
FRA:2E9's PB Ratio is ranked better than 70.19% of 1231
companies
in the Biotechnology industry
Industry Median: 2.82
vs FRA:2E9: 1.57
During the past 12 months, Intervacc AB's average Book Value Per Share Growth Rate was -26.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -39.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -29.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -17.00% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Intervacc AB was 6.70% per year. The lowest was -39.80% per year. And the median was -18.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Intervacc AB PB Ratio Related Terms
Intervacc AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Intervacc AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Intervacc AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Intervacc AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Intervacc AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Intervacc AB (FRA:2E9) has a PB Ratio of 1.30 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Intervacc AB and its competitors. This is 27% below median its historical median of 1.79. Over the past decade, Intervacc AB's PB Ratio has ranged from 0.30 to 13.50. According to the industry distribution chart, Intervacc AB ranks #367 out of 1231 companies in the Biotechnology industry, placing it in the top 29.8%.
Is Intervacc AB's PB Ratio too high?
Intervacc AB's current PB Ratio of 1.30 is 27% below median its 10-year median of 1.79. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 13.50. The Biotechnology industry median PB Ratio is 2.82. Intervacc AB's value of 1.30 is 53.9% below this industry median. Based on the distribution chart, Intervacc AB ranks #367 out of 1231 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #367 out of 1231 companies for PB Ratio. This puts Intervacc AB in the upper half of its industry. The industry median PB Ratio is 2.82. Intervacc AB's value of 1.30 is 53.9% below this benchmark. Historically, Intervacc AB's own PB Ratio has ranged from 0.30 to 13.50 over the past decade. While the company's 10-year median is 1.79 vs. the industry median of 2.82, Intervacc AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intervacc AB's current PB Ratio of 1.30 is 53.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Intervacc AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intervacc AB's current PB Ratio is 1.30, which is 27% below median its own 10-year median of 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current PB Ratio of 1.30. The stock's GF Value™ is €0.09, compared to a current price of €0.09 — trading 0.3% below its estimated fair value. The current PB Ratio is 1.30, which is 27% below median its 10-year median of 1.79 and 53.9% below the Biotechnology industry median of 2.82. Intervacc AB's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current PB Ratio is 1.30 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be undervalued.
The current stock price of €0.09 is trading 0.3% below its estimated GF Value™ of €0.09.
Key valuation signals for FRA:2E9:
PB Ratio: 1.30 (27% below median its 10-year median of 1.79)
GF Value™: €0.09 vs. price of €0.09 (0.3% below fair value)
Industry Position: 53.9% below the Biotechnology median (#367 of 1231)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score
Get the complete analysis for FRA:2E9
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
